CJC-1295 vs Sermorelin
A detailed comparison to help you understand the differences and choose the right peptide for your research.
CJC-1295 and Sermorelin are both GHRH (Growth Hormone Releasing Hormone) analogs that stimulate natural GH production. While they share the same receptor target, key differences in structure and half-life affect how they're used. Understanding these differences helps optimize GH enhancement protocols.
Quick Comparison
Key Similarities
- Both are GHRH analogs
- Both stimulate pituitary GH release
- Both maintain natural feedback mechanisms
- Both can be combined with GHRPs
- Both are generally well-tolerated
- Both produce physiological GH patterns (no DAC versions)
Key Differences
- CJC-1295 has a longer half-life
- CJC-1295 DAC provides sustained GH elevation
- Sermorelin has more clinical history
- Sermorelin was FDA-approved (discontinued)
- CJC-1295 no-DAC is more commonly paired with GHRPs
- Sermorelin simpler dosing (once daily)
When to Choose Each
Choose CJC-1295
Choose CJC-1295 when you want flexibility between pulsatile (no DAC) and sustained (with DAC) GH release. The no-DAC version is excellent for combining with GHRPs for synergistic effects.
Choose Sermorelin
Choose Sermorelin for its extensive clinical history and straightforward once-daily dosing. It's well-suited for those who prefer a proven, traditional approach to GH enhancement.
Can You Stack Them?
Both peptides synergize with GHRPs like Ipamorelin. CJC-1295 no-DAC + Ipamorelin is one of the most popular combinations. Sermorelin + Ipamorelin is equally effective and commonly used in clinical settings.
Frequently Asked Questions
References
- Teichman SL, et al. "CJC-1295 GH effects." J Clin Endocrinol Metab, 2006. PMID: 16595485
- Walker RF. "Sermorelin review." Drugs, 2006. PMID: 16929329
Get the Complete Comparison Guide
Download our detailed comparison charts and decision framework.